Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | TK2 | O00142 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4264417 | 1.00 | TK1 (0.64) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL7166600 | 0.94 | TK1 (0.61) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL7166605 | 0.94 | TK1 (0.61) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL7173806 | 0.93 | TK1 (0.60) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL7173802 | 0.93 | TK1 (0.60) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL7168840 | 0.92 | TK1 (0.59) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL7168837 | 0.92 | TK1 (0.59) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL933039 | 0.92 | TK1 (0.66) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL933041 | 0.92 | TK1 (0.66) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL4274511 | 0.91 | TK1 (0.66) | TK1LMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119546776-A | Variant allele enrichment by unidirectional double probe primer extension | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119325511-A | Methods, compositions and kits for inhibiting linker dimer formation | 柏尔科学公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-118355129-A | Method for capturing CRISPR endonuclease cleavage products | 卡里布生物科学公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117859062-A | Multiple assay plate and method of making same | 中尺度技术有限责任公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2024073740-A2 | IMPROVED LOOP–MEDIATED ISOTHERMAL AMPLIFICATION METHODS, COMPOSITIONS, KITS, AND SYSTEMS FOR DETECTING NUCLEIC ACIDS | 3EO HEALTH INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-117730155-A | Enhancer oligonucleotides for nucleic acid hybridization | 豪夫迈·罗氏有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-116964221-A | Structure for preventing nucleic acid templates from passing through nanopores during sequencing | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116368236-A | Polynucleotide array | 牛津大学创新有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116348614-A | Switching oligonucleotides | 牛津大学创新有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-115968409-A | Compositions and methods for sequencing using polymer bridges | 伊鲁米纳公司 | 2023-04-14 | — | — | CN | disclosed |
| US-6339151-B1 | FORMING COMPOUNDS USING A NUCLEIC ACID BASE WITH A PHOSPHOROUS HALIDE TO FORM DRUGS FOR NONPROLIFERATION OF CELLS | NEWBIOTICS, INC. | 2002-01-15 | — | — | US | disclosed |
| EP-1167972-A2 | Enzyme catalyzed therapeutic agents | Newbiotics Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| US-20010034440-A1 | Enzyme catalyzed therapeutic agents | KIADIS PHARMA INTELLECTUAL PROPERTY B.V. (NL) | 2001-10-25 | — | — | US | disclosed |
| US-6245750-B1 | THYMIDINE PHOSPHORAMIDE DERIVATIVE; ANTIPROLIFERATIVE, ANTICARCINOGENIC AGENTS; ENZYME INHIBITORS; | NEWBIOTICS, INC. | 2001-06-12 | — | — | US | disclosed |
| WO-2001007087-A2 | ENZYME CATALYZED ANTI-INFECTIVE THERAPEUTIC AGENTS | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007088-A2 | METHODS FOR TREATING THERAPY-RESISTANT TUMORS | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007454-A1 | ENZYME CATALYZED THERAPEUTIC ACTIVATION | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1045897-A4 | ENZYME CATALYZED THERAPEUTIC AGENTS | NEWBIOTICS INC (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1045897-A1 | ENZYME CATALYZED THERAPEUTIC AGENTS | Newbiotics Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999037753-A1 | ENZYME CATALYZED THERAPEUTIC AGENTS | NEWBIOTICS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034440-A1 | Enzyme catalyzed therapeutic agents | DNPEP, AGBL2, ENTPD2 | TK1 7/4885LMNA 2990/4885SMN1; SMN2 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.